iqvia weight loss drug prescriptions q3 2024 semaglutide tirzepatide Massive sales for drugs spur Eli Lilly's iqvia weight loss drug prescriptions

Discussion : Weight gain can be an adverse effect in breast cancer treatment and can significantly impact on a patient's quality of life and long-term prognosis

By the early 1990s, research demonstrated their effectiveness at managing the symptoms of type-2 diabetes

Anticancer Drugs 4 , 637640 (1993)

These synthetic analogs possess significantly long half-life and are now used clinically

In response, FDA has clarified its timeline for enforcement against compounders making knockoffs of these diabetes and weight loss medicines: State-licensed compounding pharmacies must stop selling tirzepatide immediately andunless OFAs other injection request is dismissed earliermay continue selling semaglutide until April 22, 2025